Clinical trial
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT00430677 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00430677 |
|---|---|
| Title | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis |
| Official title | A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus… |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF) |
| Enrollment | 423 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Aug 1, 2011 |
| First posted | Feb 2, 2007 |
| Last update posted | Mar 20, 2015 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, China, France, Hong Kong, India, Mexico, Poland, Russia and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: